Gary DeCrescenzo

Physiochemical drug properties associated with in vivo toxicological outcomes

Jason D. Hughes, Julian Blagg, David A. Price et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 945 citations

Preclinical Drug Evaluation, Medicine, Toxicology +5

Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature

Steven Seaman, Zhongyu Zhu, Saurabh Saha et al. · Cancer Cell · 2017 · 427 citations

Cd276/b7-h3-positive Tumor Cells, Simultaneous Ablation, Medicine +10

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Ryan J. Sullivan, Jeffrey R. Infante, Filip Jankú et al. · Cancer Discovery · 2017 · 401 citations

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)

Ursula A. Germann, Brinley F. Furey, William Markland et al. · Molecular Cancer Therapeutics · 2017 · 225 citations

Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere

Daniel P. Getman, Gary DeCrescenzo, R. Heintz et al. · Journal of Medicinal Chemistry · 1993 · 178 citations · Full text

Pharmaceutical Science, Altmetric Attention Score, Pharmacotherapy +16